|EMD Serono, unit of Merck KGaA, of Darmstadt, Germany||M-5049||Dual TLR-7/TLR-8 antagonist||COVID-19 infection||FDA cleared IND for phase II study assessing effect on preventing or ameliorating hyper-inflammatory response in COVID-19 pneumonia and preventing progression to cytokine storm; study expected to enroll ~150 participants in U.S. and Brazil, with top-line data expected by year-end 2020|
|Genprex Inc., of Austin, Texas||GPX-001||TUSC2 gene stimulator||Non-small-cell lung cancer||United States Adopted Names Council approved non-proprietary name quaratusugene ozeplasmid for GPX-001, formerly called Oncoprex|
|Medivir AB, of Stockholm||MIV-818 (liver-targeted troxacitabine prodrug)||DNA polymerase inhibitor||Hepatocellular carcinoma||EC granted orphan medicinal product designation in the EU|
|Merck and Co. Inc., of Kenilworth, N.J.||Keytruda (pembrolizumab)||PD-1 inhibitor||Cutaneous squamous cell carcinoma||FDA approved drug as monotherapy to treat recurrent or metastatic disease not curable by surgery or radiation, based on data from phase II Keynote-629 trial|
|Sinovac Biotech Ltd., of Beijing||Quadrivalent influenza vaccine||Split virion influenza vaccine||Influenza infection||NMPA approved product in China to protect against 2 A strains and 2 B strains of influenza in individuals 3 years and older|
|Tizona Therapeutics Inc., of South San Francisco||TTX-080||Anti-HLA-G antibody||Advanced cancer||FDA cleared IND for phase I study, expected to begin in third quarter of 2020, evaluating TTX-080 both as monotherapy and in combination therapy|
|Viracta Therapeutics Inc., of San Diego||Nanatinostat + valganciclovir||Histone deacetylase inhibitor||T-cell lymphoma||FDA granted orphan drug designation in the indication|
For more information about individual companies and/or products, see Cortellis.